010600 — WellBiotec Co Income Statement

0.000.00%

Last trade - 00:00

Consumer CyclicalsHighly SpeculativeMicro Cap

Annual income statement for WellBiotec Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS/A	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	52,333	60,431	108,377	158,116	72,132
Cost of Revenue
Gross Profit	8,512	6,408	9,288	22,220	9,940
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	56,290	103,805	120,520	161,368	93,532
Operating Profit	-3,957	-43,373	-12,143	-3,252	-21,400
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-5,433	-51,129	-34,555	-19,633	-65,856
Provision for Income Taxes
Net Income After Taxes	-5,587	-50,908	-34,879	-21,024	-66,372
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-15,298	-67,431	-33,279	-20,881	-64,910
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-15,298	-67,431	-33,279	-20,881	-64,976
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-175	-707	-538	-269	-775
Dividends per Share